|  Help  |  About  |  Contact Us

Publication : The Parkinson's disease-associated gene ITPKB protects against α-synuclein aggregation by regulating ER-to-mitochondria calcium release.

First Author  Apicco DJ Year  2021
Journal  Proc Natl Acad Sci U S A Volume  118
Issue  1 PubMed ID  33443159
Mgi Jnum  J:300022 Mgi Id  MGI:6492380
Doi  10.1073/pnas.2006476118 Citation  Apicco DJ, et al. (2021) The Parkinson's disease-associated gene ITPKB protects against alpha-synuclein aggregation by regulating ER-to-mitochondria calcium release. Proc Natl Acad Sci U S A 118(1):e2006476118
abstractText  Inositol-1,4,5-triphosphate (IP3) kinase B (ITPKB) is a ubiquitously expressed lipid kinase that inactivates IP3, a secondary messenger that stimulates calcium release from the endoplasmic reticulum (ER). Genome-wide association studies have identified common variants in the ITPKB gene locus associated with reduced risk of sporadic Parkinson's disease (PD). Here, we investigate whether ITPKB activity or expression level impacts PD phenotypes in cellular and animal models. In primary neurons, knockdown or pharmacological inhibition of ITPKB increased levels of phosphorylated, insoluble alpha-synuclein pathology following treatment with alpha-synuclein preformed fibrils (PFFs). Conversely, ITPKB overexpression reduced PFF-induced alpha-synuclein aggregation. We also demonstrate that ITPKB inhibition or knockdown increases intracellular calcium levels in neurons, leading to an accumulation of calcium in mitochondria that increases respiration and inhibits the initiation of autophagy, suggesting that ITPKB regulates alpha-synuclein pathology by inhibiting ER-to-mitochondria calcium transport. Furthermore, the effects of ITPKB on mitochondrial calcium and respiration were prevented by pretreatment with pharmacological inhibitors of the mitochondrial calcium uniporter complex, which was also sufficient to reduce alpha-synuclein pathology in PFF-treated neurons. Taken together, these results identify ITPKB as a negative regulator of alpha-synuclein aggregation and highlight modulation of ER-to-mitochondria calcium flux as a therapeutic strategy for the treatment of sporadic PD.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

1 Bio Entities

Trail: Publication

0 Expression